Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	$ (23,194)	$ (31,350)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt	4,421
Gain on sale of Agera	(467)
Stock issued for exclusive channel collaboration agreement	6,917
Stock-based compensation expense	1,224	2,900
Warrant revaluation (income) expense	(8,725)	4,763
Derivative revaluation expense	23	5,451
Deferred tax benefit	(2,500)
Depreciation and amortization	821	158
Provision for doubtful accounts	25	18
Provision for excessive and/or obsolete inventory		(46)
Amortization of debt issue costs	146
Change in operating assets and liabilities:
Increase in accounts receivable	(60)	(4)
Increase in other receivables		(1)
(Increase) decrease in inventory	(477)	38
Increase in prepaid expenses	(196)	(437)
Increase (decrease) in accounts payable	(966)	804
Increase in accrued expenses and other liabilities	407	816
Increase in deferred revenue	83	55
Increase in miscellaneous other	(57)	(2)
Net cash used in operating activities	(22,575)	(16,837)
Cash flows from investing activities:
Purchase of property and equipment	(493)	(1,570)
Proceeds from the sale of Agera	1,002
Net cash provided by (used in) investing activities	509	(1,570)
Cash flows from financing activities:
Offering costs associated with the issuance of debt	(46)	(100)
Proceeds from the issuance of redeemable preferred stock series B, D and E, net	7,864	5,836
Proceeds from the exercise of warrants		2,419
Proceeds from the issuance of common stock, net	40,185	22,168
Payments on insurance loan	(97)	(81)
Principal payments on 12.5% note payable	(4,823)	(1,283)
Cash dividends paid on preferred stock	(470)	(623)
Net cash provided by financing activities	42,613	28,336
Effect of exchange rate changes on cash balances		2
Net increase in cash and cash equivalents	20,547	9,931
Cash and cash equivalents, beginning of period	10,799	868
Cash and cash equivalents, end of period	$ 31,346	$ 10,799